The other two fusion events (FAM168A-RAB6A and UPF3A-CDC16) have been reported in solid cancers (FAM168A-RAB6A in lung cancer and UPF3A-CDC16 in thyroid cancer), both of which have the same junction breakpoints as the previous reports [26]. Here, UPF3A is linked to thyroid gland carcinoma.